Precision Oncology Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures, Licensing and Monetization, Peer Comparison Analysis, Leadership and Governance

Precision Oncology Companies, Business & Management Outlook

The global precision oncology market is projected to grow from USD 120.9 billion in 2024 to USD 310.75 billion by 2034, representing a robust compound annual growth rate (CAGR) of 9.9% over the period from 2024 to 2034.

Top Companies in the Precision Oncology Market

• AbbVie
• ACT Oncology
• AstraZeneca
• Bristol Myers Squibb
• Gilead Sciences
• Illumina, Inc.
• Insilico Medicine
• Johnson & Johnson
• Maze Therapeutics, Inc.
• Myriad Genetics
• Novartis
• Pfizer
• Qiagen N.V.
• Roche Diagnostics

Recent Developments in the Precision Oncology Market

• In October 2024, the National Institute of Health launched the myeloMATCH precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) cancer cells.
• In April 2024, LabCorp announced the expansion of its precision oncology portfolio to advance cancer research and patient care on a global scale. It launched a novel platform for molecular residual disease (MRD), Labcorp Plasma Detect, for ctDNA genomic profiling solution.

Consignment and Shipper Details of Pharma Products in the U.S.